Aelis Farma was founded after the discovery by Dr. Pier Vincenzo Piazza, Dr. Giovanni Marsicano and their teams, at the INSERM Neurocentre Magendie in Bordeaux, that the neurosteroid pregnenolone, previously known as an inactive precursor of all steroids, is in fact an endogenous “signaling specific negative modulator” of the most expressed GPCR (G-Protein Coupled Receptor) in the brain: the CB1 receptor.
Pregnenolone is spontaneously produced in the brain when CB1 receptors are over-activated. Pregnenolone then binds to a specific site on the CB1 receptor and selectively blocks one of the cellular effects of CB1 activation: the stimulation of the MAP-kinase pathway thus reducing most of THC behavioral effects.
Unfortunately, because of a very poor bioavailability and its conversion into other steroids, pregnenolone is not a druggable compound.
For this reason, Aelis Farma is developing a new pharmacological class: Signaling Specific Inhibitors (SSi).
These derivatives, like pregnenolone, selectively inhibit the THC mediated CB1 receptor activation, but inversely have a good bioavailability and are not converted into other steroids.